We're excited to share Memorial Sloan Kettering Cancer Center (MSK)'s bold new advertising campaign “This Is What We Do.” From a jazz musician whose life was saved by precision oncology, to a prostate cancer patient who has become an advocate for early detection, the stories we share throughout this campaign reflect our shared mission and the extraordinary outcomes we achieve together. 🔹 This is treatment on a cellular level. ​ 🔹 This is care on a personal level. ​ 🔹 This is hope on another level. ​ When someone receives a cancer diagnosis, we want them to know exactly what to do next: come to MSK. And when patients choose MSK, they’re choosing better, longer lives. Learn more: bit.ly/3SgwqKj

New editorial by Drs. Gleneara E. Bates-Pappas Jamie S. Ostroff of @MSKCancerCenter | Breaking barriers: Opt-out tobacco dependence treatment in oncology care acsjournals.onlinelibrary.wi… @OncoAlert

For years, patients with triple negative #breastcancer (#TNBC) have had limited treatment options beyond chemotherapy. Now, based on results from the MSK-led TROPION-Breast02 trial, Dato-DXd was FDA approved in May 2026 as first-line therapy for adults with advanced HER2 negative breast cancer who have already received endocrine-based therapy and chemotherapy, making it the first TROP2-directed ADC to gain FDA approval as first-line in this patient population. “Dato-DXd significantly improved overall survival for this challenging subtype of breast cancer, where historic median overall survival has been about 12 months,” said Dr. Tiffany Traina, lead and senior author of the study and MSK breast medical oncologist. Read more about the study: bit.ly/3QjTN5h

Can pancreatic cancer be “cold yet vaccinable”? @TheVinodLab from @MSKCancerCenter shares insights on RNA vaccines at the SCI Breakthroughs in Cancer Series. Watch the full seminar: brnw.ch/21x3gWE #PancreaticCancer

🗓️ Save the date! Join MSK’s annual Survivorship Celebration: Resilience in Motion on June 12 at 4pm ET. This event features survivorship stories, wellness practice, and expert guidance to navigate life after cancer. Featured speakers include: MSK integrative medicine specialist Dr. @JunMaoMD; MSK thoracic medical oncologist Dr. Cardinale Smith; and MSK exercise physiologist Dr. Jessica Scott, who will share science-based evidence to guide and manage survivorship. Register here: bit.ly/4urF8D6

MSK radiation oncologist Dr. Nancy Lee (@imtrlee) presented new findings at the 2026 @asco suggesting some people with HPV-related #throatcancer may be able to receive significantly lower doses of radiation while maintaining excellent outcomes. The approach could help reduce treatment-related side effects while preserving effectiveness. Learn more: bit.ly/49tCmWi

#MRFResearchWednesday – we are honored to highlight Sarah Kim of @MSKCancerCenter, recipient of an MRF Medical Student Award, with funding support provided in Memory of Peter Looney and the Looney Legacy Foundation. Sarah’s work titled, “Benign Dermoscopic Morphology by Skin Tone and Anatomic Site”, will create a diverse image database of benign skin lesions across all skin tones to improve diagnosis, reduce unnecessary biopsies and help ensure future AI tools work effectively for everyone. Of her work, Sarah offers, “This research aims to build a diverse image database of benign skin lesions seen through dermoscopy, helping dermatologists better recognize these common skin findings across different skin tones and body sites. By improving our understanding of what benign lesions look like in diverse patients, we hope to support more accurate melanoma detection, reduce unnecessary biopsies, and help ensure that patients of all skin tones receive thoughtful, equitable skin cancer care." To learn more about Sarah’s work, click here: melanoma.org/news-press/rese…

Congratulations to MSK's most recent awards and appointments, including @YJanjigianMD, Dr. Samuel Cytryn, and Dr. Jeremy Tchack for being awarded funding by the Torrey Coast Foundation; Dr. Scott Lowe for receiving the 2026 Lotus Award from the @PershingSqFdn; Dr. Kathleen Foley for being inducted into the Giants of Cancer Care Class of 2026; and more: bit.ly/4xh2PAC

On June 8–9, Dr. Carol Brown, the Associate Cancer Center Director for Diversity and Outreach at MSK, will meet with experts at the #PresCancerPanel to explore the evidence linking modifiable risk factors to cancer and discuss opportunities to reduce cancer risk. MSK breast surgeon Dr. Neha Goel will also present at this event. Learn more: bit.ly/3RNmW9n

WATCH 👀: @ggardnermd of @MSKCancerCenter discusses the importance of elevating the national conversation surrounding gynecologic cancers through collaborative efforts. See the whole video here ➡️: onclive.com/view/dr-gardner-… #gyncsm #oncology

Honored to have completed my observership at @MSKCancerCenter under the mentorship of @GABOUALFA. Grateful for the opportunity to learn from leaders in GI oncology at one of the world’s top cancer centers. Thank you to the 2026 IDEA @ConquerCancerFd and @ASCO @icesi @FVLCali

In a randomized, international phase 3 trial, @EileenMOReilly et al. at @MSKCancerCenter and Dana Farber Institute gave previously treated metastatic pancreatic cancer patients either chemotherapy or the experimental oral medication daraxonrasib. Treatment with daraxonrasib led to significantly longer overall survival and progression-free survival than chemo, per @NEJM study: ow.ly/Nyom50Z6o4K

Finally some warm weather, beautiful evening out at our annual Myeloma Service picnic in the park this week!! #mmsm @MSKCancerCenter @MSK_DeptOfMed

🆕 #ASCO26 data in unresectable #HCC. Ghassan K. Abou-Alfa, MD, PhD, FASCO, of @MSKCancerCenter discusses efficacy and safety findings from the phase III EMERALD-3 trial evaluating immunotherapy-based combinations with TACE. 🎥 Watch here: ascopost.com/videos/asco-202…

Congratulations to MSK's @Joshua_M_Weiss for being selected as a 2026 @CureMelanoma Grant Recipient! 🎉

Congratulations to our @MSKCancerCenter graduating body imaging fellows and cardiac imaging 🫀fellow!

🆕 #ASCO26 data in dedifferentiated #liposarcoma. Mark A. Dickson, MD, of @MSKCancerCenter, discusses SARC041 findings showing a statistically significant progression-free survival benefit with abemaciclib in advanced dedifferentiated liposarcoma. 🎥: ascopost.com/videos/asco-202…

Thank you to everyone who participated in Memorial Sloan Kettering Cancer Center (MSK)'s #NYCforMSK and made the event so special. On May 29, 35 iconic New York City brands came together to celebrate MSK’s 142nd anniversary and support lifesaving research and care. Thank you to all of our partners and for everyone who shopped, donated, or even brought your pup to Madison Avenue, every act of generosity made a difference. Learn more and donate here: bit.ly/43SbtrD

Congratulations to Dr. Martin Weiser, who has been selected to serve serve as the next Chair of the Department of Surgery at MSK. Dr. Weiser currently holds the Stuart H.Q. Quan Chair in Colorectal Surgery, is a world-renowned academic colorectal surgeon, and has held a number of important leadership roles in his 25 years on the faculty at MSK, including serving for the past 10 months as the Acting Department Chair. Join us in welcoming Dr. Weiser to the role of Chair of the Department of Surgery by commenting below. 👏

🏙️ Desde Chicago, en #ASCO26 @ASCO ⭕️ Vídeo de highlights #CáncerdePulmón en onconexion.es 🩺 El Dr. Jaime Rubio, de @MSKCancerCenter, resume las novedades más relevantes: avances en terapias dirigidas para RET, ALK y EGFR (LIBRETTO-432, LORIN, CROWN y WU-KONG28), nuevos datos de inmunoterapia en HARMONi-6 y estrategias innovadoras con ADCs en enfermedad metastásica #OncoNexion26 👇🏻

A landmark moment for pancreatic cancer, these findings highlight what transformative progress can look like. Congratulations to @EileenMOReilly & team @MSKCancerCenter advancing this research driving forward a new standard of care in a disease that has long needed breakthroughs